Phenotypes associated with this allele

• Allele Symbol: Cdkn2a^tm1Cjs
• Allele Name: targeted mutation 1, Charles J Scherr
• Allele ID: MGI:1926877
• Summary: 22 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs	involves: 129X1/SvJ	MGI:3027936
hm2	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs	involves: 129X1/SvJ * C57BL/6	MGI:2175770
hm3	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs	involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd	MGI:3774767
ht4	Cdkn2a^tm1Cjs/Cdkn2a^+	involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd	MGI:3774768
cn5	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Nop53^tm2.1Asuz/Nop53^tm2.1Asuz Tg(Lck-cre)#Jxm/0	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA	MGI:5906183
cn6	Bmi1^tm1Brn/Bmi1^tm1Brn Apc^tm2Cip/Apc^+ Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Tg(Vil1-cre)20Syr/0	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2	MGI:5532576
cx7	Cdkn2a^tm1Cjs/Cdkn2a^+ Ppm1d^tm1Lad/Ppm1d^tm1Lad Tg(IghMyc)22Bri/0	involves: 129 * C57BL * FVB/N * SJL	MGI:3710182
cx8	Cdkn2a^tm1Cjs/Cdkn2a^+ Tgfb2^tm1Doe/Tgfb2^tm1Doe	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6	MGI:3848999
cx9	Cdkn2a^tm1Cjs/Cdkn2a^+ Kat5^tm1Jwl/Kat5^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:3814377
cx10	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Trp53^tm1Tyj/Trp53^tm1Tyj	involves: 129S2/SvPas * 129X1/SvJ * C57BL/6	MGI:3694644
cx11	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Pax7^tm1Pgr/Pax7^+ Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0	involves: 129S2/SvPas * 129X1/SvJ * FVB	MGI:5882414
cx12	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Pax7^tm1Pgr/Pax7^tm1Pgr Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0	involves: 129S2/SvPas * 129X1/SvJ * FVB	MGI:5882413
cx13	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Pdgfrb^tm1Sor/Pdgfrb^tm1Sor	involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6	MGI:3694645
cx14	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Trp53^tm1Brd/Trp53^tm1Brd	involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd	MGI:3774770
cx15	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Tg(GFAP-TVA)5Hev/0	involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB/N	MGI:3835355
cx16	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Tacstd2^tm1Lsm/Tacstd2^tm1Lsm	involves: 129X1/SvJ * C57BL/6	MGI:5316864
cx17	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Gt(ROSA)26Sor^tm1.1(MYC/ERT2)Gev/Gt(ROSA)26Sor^tm1.1(MYC/ERT2)Gev	involves: 129X1/SvJ * C57BL/6 * FVB/N	MGI:3821934
cx18	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Tg(NES-TVA)J12Ech/0	involves: 129X1/SvJ * C57BL/6 * FVB/N	MGI:3835358
cx19	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0	involves: 129X1/SvJ * FVB	MGI:5882410
cx20	Cdkn2a^tm1Cjs/Cdkn2a^+ Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0	involves: 129X1/SvJ * FVB	MGI:5882411
cx21	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Sclt1^Tg(CAG-sb10)1Dla/0 TgTn(sb-T2/Onc)76Dla/0	involves: 129X1/SvJ * FVB/N	MGI:3613023
cx22	Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Sclt1^Tg(CAG-sb10)1Dla/0 TgTn(sb-T2/Onc)68Dla/0	involves: 129X1/SvJ * FVB/N	MGI:3613024

Genotype
MGI:3027936

hm1

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs
• Genetic Background: involves: 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

reproductive system

oligozoospermia ( J:147752 )

♂ • with age, sperm counts in males decrease to about one quarter by 17 weeks

decreased testis weight ( J:147752 )

♂ • from 4 weeks onward, males display decreased testis weight

testicular atrophy ( J:147752 )

♂ • males display increasing testicular atrophy with age

vision/eye

blindness ( J:147752 )

• 3-month old animals are completely blind

cellular

oligozoospermia ( J:147752 )

♂ • with age, sperm counts in males decrease to about one quarter by 17 weeks

endocrine/exocrine glands

decreased testis weight ( J:147752 )

♂ • from 4 weeks onward, males display decreased testis weight

testicular atrophy ( J:147752 )

♂ • males display increasing testicular atrophy with age

Genotype
MGI:2175770

hm2

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs
• Genetic Background: involves: 129X1/SvJ * C57BL/6

Abnormal retrolental tissue present in the eyes of neonatal Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs mice

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:44427 )

decreased testis weight ( J:244260 )

♂

neoplasm

increased tumor incidence ( J:44427 )

• by 2 months of age,tumors began to develop and by 6 months 6 of 18 mice had malignant tumors

increased incidence of tumors by chemical induction ( J:44427 )

• following DMBA treatment 1 week after birth, 9 of 11 mice developed skin tumors by 9-20 weeks of age with 2 mice developing invasive epidermoid carcinomas and 3 mice developing 2 tumors of different histological types

• DMBA induced tumors skin tumors occurred at multiple sites and had varying degrees of anaplasia

increased fibrohistocytoma incidence ( J:44427 )

• malignant fibrous histocytoma

increased acute lymphoblastic leukemia incidence ( J:244260 )

• when p185^BCR-ABL positive pro/pre-B cells from cultured bone marrow progenitors from mice with this genotype were injected into wild-type mice

increased lymphoma incidence ( J:44427 )

• in the brain

increased T cell derived lymphoma incidence ( J:44427 )

increased carcinoma incidence ( J:44427 )

• metastatic salivary gland carcinoma

increased fibrosarcoma incidence ( J:44427 )

• 2 of 18 had fibrosarcomas

increased incidence of tumors by ionizing radiation induction ( J:44427 )

• following gamma-irradiation of newborn mice, 4 of 6 mice developed fibrosarcomas or anaplastic T cell lymphomas

reproductive system

oligozoospermia ( J:244260 )

♂ • with increasing age

abnormal spermatocyte morphology ( J:244260 )

♂ • p53-dependent apoptosis during pachytene

decreased testis weight ( J:244260 )

♂

cellular

oligozoospermia ( J:244260 )

♂ • with increasing age

abnormal spermatocyte morphology ( J:244260 )

♂ • p53-dependent apoptosis during pachytene

abnormal cell physiology ( J:44427 )

• MEFs were less responsive to contact-induced growth inhibition

increased fibroblast proliferation ( J:44427 )

• MEFs showed increased proliferative capacity, faster growth rate, and no senescence crisis was ever detected

vision/eye

vision/eye phenotype ( J:149526 )

N • despite expression in the cornea, no obvious thinning of the cornea is detected

abnormal lens morphology ( J:75215 )

• at around P14, the lens undergoes degenerative changes characterized by vacuolization and lens material degradation; an attempt at lens repair beyond P14 is manifested by the accumulation of lens epithelial cells lining a regenerated posterior capsule

• attachment of the retrolental tissue to the posterior lens and extrusion of lens material into the retrolental tissue

abnormal lens capsule morphology ( J:75215 )

• lens capsule destruction

persistent hyperplastic primary vitreous ( J:75215 , J:149526 )

• failure of hyaloid vascular regression that causes a pathological process that resembles persistent hyperplastic primary vitreous (J:75215)

• proliferation continues in the hyperplastic primary vitreous at E18.5 (J:149526)

primary vitreous hyperplasia ( J:101016 )

• show increased cell proliferation in the developing vitreous between E12.5 and E13.5

microphthalmia ( J:75215 )

abnormal retina morphology ( J:75215 )

• at P14 and beyond, the neuroretina is abnormal, with the presence of retinal folds, progressive physical attachment of the retrolental mass to the neuroretina, and progressive detachment of the neuroretina from the retina pigment epithelium

abnormal retina photoreceptor morphology ( J:75215 )

• at P14 and beyond, the retina exhibits rosette-like arrangements of dysplastic photoreceptor cells

abnormal retina ganglion layer morphology ( J:75215 )

• in the areas where observe progressive physical attachment of the retrolental mass to the neuroretina, the ganglion cell layer is disorganized

abnormal retina inner nuclear layer morphology ( J:75215 )

• in the areas where observe progressive physical attachment of the retrolental mass to the neuroretina, the inner nuclear cell layer is disorganized

retina detachment ( J:75215 , J:244260 )

• at P14 and beyond, exhibit progressive detachment of the neuroretina from the retina pigment epithelium (J:75215)

• caused by aberrant accumulation of mural pericytes and development of a retrolental mass in early postnatal period (J:244260)

retina fold ( J:75215 )

• presence of retinal folds at P14 and beyond

binocular blindness ( J:244260 )

• retina detaches and collapses into lens in early postnatal period

nervous system

abnormal retina photoreceptor morphology ( J:75215 )

• at P14 and beyond, the retina exhibits rosette-like arrangements of dysplastic photoreceptor cells

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:44427 )

• following DMBA treatment 1 week after birth, 9 of 11 mice developed skin tumors by 9-20 weeks of age with 2 mice developing invasive epidermoid carcinomas and 3 mice developing 2 tumors of different histological types

• DMBA induced tumors skin tumors occurred at multiple sites and had varying degrees of anaplasia

integument

increased fibrohistocytoma incidence ( J:44427 )

• malignant fibrous histocytoma

immune system

increased T cell derived lymphoma incidence ( J:44427 )

hematopoietic system

increased T cell derived lymphoma incidence ( J:44427 )

Genotype
MGI:3774767

hm3

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd

Metastasis of primary squamous cell carcinoma to lymph nodes and lungs in Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs mice

neoplasm

increased incidence of tumors by chemical induction ( J:93298 )

• by 20 weeks after a single dose of DMBA and twice weekly application of TPA for 15 weeks, mutants show an increase in papilloma number and size compared to wild-type

increased metastatic potential ( J:93298 )

• mutants treated with DMBA/TPA exhibit increased dissemination of squamous cell carcinomas to lymph nodes and lungs compared to wild-type

increased tumor growth/size ( J:93298 )

• by 28 weeks after DMBA/TPA treatment, 33% of papillomas are greater than 8 mm vs. 14% from wild-type and can measure up to 16 mm in diameter which is never seen in wild-type

increased carcinoma incidence ( J:93298 )

• rate of malignant conversion from papillomas to carcinomas is accelerated in mutants treated with DMBA/TPA, with carcinomas developing as early as 14 weeks after initiation, compared to 22 weeks in wild-type

• by 28 weeks, 100% of mutants treated with DMBA/TPA develop carcinomas compared to 25% of wild-type

increased squamous cell carcinoma incidence ( J:93298 )

• mutants treated with DMBA/TPA to induce tumors exhibit increased dissemination and establishment of squamous cell carcinomas to lymph nodes and lungs compared to treated wild-type mice

increased papilloma incidence ( J:93298 )

• mutants have an average of 2.97 more papillomas than wild-type after DMBA/TPA treatment

• all papillomas contain an AT transversion at codon 61 of Hras, resulting in a constitutively activated Ras protein, and reduced expression of Trp53

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:93298 )

• by 20 weeks after a single dose of DMBA and twice weekly application of TPA for 15 weeks, mutants show an increase in papilloma number and size compared to wild-type

Genotype
MGI:3774768

ht4

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a⁺
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd

neoplasm

increased incidence of tumors by chemical induction ( J:93298 )

• by 20 weeks after a single dose of DMBA and twice weekly application of TPA for 15 weeks, mutants show an increase in papilloma number and size compared to wild-type

• tumors of heterozygous mice show loss of heterozygosity during benign to malignant conversion

increased carcinoma incidence ( J:93298 )

• by 28 weeks, 60% of DMBA/TPA treated heterozygotes develop carcinomas compared to 25% of wild-type

increased papilloma incidence ( J:93298 )

• mutants have an average of 2.6 more papillomas than wild-type after DMBA/TPA treatment

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:93298 )

• by 20 weeks after a single dose of DMBA and twice weekly application of TPA for 15 weeks, mutants show an increase in papilloma number and size compared to wild-type

• tumors of heterozygous mice show loss of heterozygosity during benign to malignant conversion

Genotype
MGI:5906183

cn5

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Nop53^tm2.1Asuz/Nop53^tm2.1Asuz; Tg(Lck-cre)#Jxm/0
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA

endocrine/exocrine glands

decreased thymocyte number ( J:241062 )

• thymocyte level was 5% of control

hematopoietic system

decreased thymocyte number ( J:241062 )

• thymocyte level was 5% of control

immune system

decreased thymocyte number ( J:241062 )

• thymocyte level was 5% of control

Genotype
MGI:5532576

cn6

• Allelic Composition: Bmi1^tm1Brn/Bmi1^tm1Brn; Apc^tm2Cip/Apc⁺; Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Tg(Vil1-cre)20Syr/0
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2

growth/size/body

cachexia ( J:204354 )

• found in some animals by 90 days of age

behavior/neurological

hunched posture ( J:204354 )

• hunching appears in some animals at 90 days of age

neoplasm

increased intestinal adenoma incidence ( J:204354 )

• increased size and number of small intestine adenomas

digestive/alimentary system

increased intestinal adenoma incidence ( J:204354 )

• increased size and number of small intestine adenomas

Genotype
MGI:3710182

cx7

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a⁺; Ppm1d^tm1Lad/Ppm1d^tm1Lad; Tg(IghMyc)22Bri/0
• Genetic Background: involves: 129 * C57BL * FVB/N * SJL

mortality/aging

premature death ( J:120284 )

• the median lifespan of >130 days

neoplasm

decreased tumor incidence ( J:120284 )

• similar to mice carrying double Ppm1d^tm1Lad allele without Cdkn2a^tm1Cjs allele, based on increased median survival time, mice carrying single Cdkn2a^tm1Cjs allele were considerably more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d⁺ allele

Genotype
MGI:3848999

cx8

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a⁺; Tgfb2^tm1Doe/Tgfb2^tm1Doe
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6

vision/eye

primary vitreous hyperplasia ( J:149526 )

Genotype
MGI:3814377

cx9

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a⁺; Kat5^tm1Jwl/Kat5⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

neoplasm

decreased tumor latency ( J:125164 )

• mice exhibit the same early tumor onset as in Cdkn2a^tm1Cjs homozygotes

Genotype
MGI:3694644

cx10

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Trp53^tm1Tyj/Trp53^tm1Tyj
• Genetic Background: involves: 129S2/SvPas * 129X1/SvJ * C57BL/6

Persistent hyperplastic primary vitreous (PHPV) in Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs mice is p53 independent

vision/eye

abnormal eye morphology ( J:75215 )

• exhibit a similar eye phenotype as seen in single Cdkn2a homozygotes that is not altered by the absence of Trp53

abnormal lens capsule morphology ( J:75215 )

• lens capsule destruction to a similar extent as in single Cdkn2a homozygotes

persistent hyperplastic primary vitreous ( J:75215 )

• failure of hyaloid vascular regression similar to that seen in single Cdkn2a homozygotes

Genotype
MGI:5882414

cx11

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Pax7^tm1Pgr/Pax7⁺; Tg(CKMM-tTA)A3Rhvh/0; Tg(tetO-Hgf,-EGFP)24Tcre/0
• Genetic Background: involves: 129S2/SvPas * 129X1/SvJ * FVB

muscle

increased rhabdomyosarcoma incidence ( J:237183 )

• mice develop mainly embryonal rhabdomyosarcoma, with 92% of tumors being embryonal rhabdomyosarcoma

neoplasm

increased sarcoma incidence ( J:237183 )

• 100% of mice develop sarcoma

• 8% of tumors are undifferentiated pleomorphic sarcoma

increased rhabdomyosarcoma incidence ( J:237183 )

• mice develop mainly embryonal rhabdomyosarcoma, with 92% of tumors being embryonal rhabdomyosarcoma

Genotype
MGI:5882413

cx12

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Pax7^tm1Pgr/Pax7^tm1Pgr; Tg(CKMM-tTA)A3Rhvh/0; Tg(tetO-Hgf,-EGFP)24Tcre/0
• Genetic Background: involves: 129S2/SvPas * 129X1/SvJ * FVB

muscle

increased rhabdomyosarcoma incidence ( J:237183 )

• 29% of tumors are embryonal rhabdomyosarcoma

neoplasm

increased sarcoma incidence ( J:237183 )

• 87% of mice develop sarcomas

• 71% of tumors that form in mice are undifferentiated pleomorphic sarcoma

increased rhabdomyosarcoma incidence ( J:237183 )

• 29% of tumors are embryonal rhabdomyosarcoma

Genotype
MGI:3694645

cx13

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Pdgfrb^tm1Sor/Pdgfrb^tm1Sor
• Genetic Background: involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6

vision/eye

abnormal vitreous body morphology ( J:101016 )

• the average number of vitreous cells in E14.5-E15.5 embryos is decreased compared to mice homozygous for Cdkn2a^tm1Cjs and heterozygous for Pdgfrb^tm1Sor

Genotype
MGI:3774770

cx14

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Trp53^tm1Brd/Trp53^tm1Brd
• Genetic Background: involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd

Tumor multiplicity and proliferation index in Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs, Trp53^tm1Brd/Trp53^tm1Brd and Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs Trp53^tm1Brd/Trp53^tm1Brd mice

neoplasm

increased tumor growth/size ( J:93298 )

• mutants show a papilloma multiplicity similar to wild-type after DMBA/TPA treatment, however tumors that develop are larger than in wild-type

abnormal tumor incidence ( J:93298 )

• tumor development is similar to wild-type after DMBA/TPA treatment although tumors are flatter and grow in an endophytic pattern compared to a highly exophytic pattern

• however, tumor progression is accelerated compared to single Trp53 homozygotes

increased carcinoma incidence ( J:93298 )

• carcinoma latency and multiplicity after DMBA/TPA is similar to that seen in single homozygous Cdkn2a mutants, however size of carcinomas is larger than in wild-type or in single Trp53 mutants

Genotype
MGI:3835355

cx15

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Tg(GFAP-TVA)5Hev/0
• Genetic Background: involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB/N

mortality/aging

premature death ( J:125535 )

• after 84 days, mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB exhibit 25% compared to 85% survival in similarly treated Tg(GFAP-TVA)5Hev mice

neoplasm

increased glioma incidence ( J:125535 )

• 20 gliomas are discovered in 26 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 3 grade II (similar to human oligodendroglioma) and 17 grade III (similar to anaplastic oligodendroglioma)

nervous system

increased glioma incidence ( J:125535 )

• 20 gliomas are discovered in 26 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 3 grade II (similar to human oligodendroglioma) and 17 grade III (similar to anaplastic oligodendroglioma)

Genotype
MGI:5316864

cx16

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Tacstd2^tm1Lsm/Tacstd2^tm1Lsm
• Genetic Background: involves: 129X1/SvJ * C57BL/6

integument

increased keratinocyte migration ( J:182647 )

• in a wound healing assay, immortalized keratinocytes exhibit increased migration compared with control cells

• however, over-expression of Tacstd2 reduces migration

increased keratinocyte proliferation ( J:182647 )

• of immortalized keratinocytes in culture

• however, over-expression of Tacstd2 reduces proliferation

abnormal skin development ( J:182647 )

• primary keratinocytes transfected with an H-Ras 12V-expressing lentivirus and transferred into nude mice exhibit increased epithelial to mesenchyme transition compared with control cells

increased skin squamous cell carcinoma incidence ( J:182647 )

• 3 of 5 sarcomatoid carcinomas that develop in mice treated with DMBA-TPA have squamous cell histology

neoplasm

increased carcinoma incidence ( J:182647 )

• 6 of 24 mice treated with DMBA-TPA develop carcinomas (sarcomtoid and poorly differentiated high grade) unlike control mice

• 5 of 6 tumors that develop in mice treated with DMBA-TPA are sarcomatoid carcinomas

• 1 of 6 tumors that develop in mice treated with DMBA-TPA are poorly differentiated high grade carcinomas

increased skin squamous cell carcinoma incidence ( J:182647 )

• 3 of 5 sarcomatoid carcinomas that develop in mice treated with DMBA-TPA have squamous cell histology

increased spindle cell carcinoma incidence ( J:182647 )

• primary keratinocytes transfected with an H-Ras 12V-expressing lentivirus and transferred into nude mice form tumors with spindle cell histology and no squamous cell histology compared with control mice which form tumors with predominantly squamous cell histology and some spindle cell components

• 5 of 6 tumors in mice treated with DMBA-TPA are sarcomatoid carcinomas

homeostasis/metabolism

enhanced wound healing ( J:182647 )

• in a wound healing assay, immortalized keratinocytes exhibit increased migration compared with control cells

• however, over-expression of Tacstd2 reduces migration

cellular

increased keratinocyte migration ( J:182647 )

• in a wound healing assay, immortalized keratinocytes exhibit increased migration compared with control cells

• however, over-expression of Tacstd2 reduces migration

increased keratinocyte proliferation ( J:182647 )

• of immortalized keratinocytes in culture

• however, over-expression of Tacstd2 reduces proliferation

Genotype
MGI:3821934

cx17

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Gt(ROSA)26Sor^{tm1.1(MYC/ERT2)Gev}/Gt(ROSA)26Sor^{tm1.1(MYC/ERT2)Gev}
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * FVB/N

cellular

increased cell proliferation ( J:142030 )

• tamoxifen treated mice exhibit increased cell proliferation in all tissues examined except colonic epithelium as in Gt(ROSA)26Sor^{tm1.1(MYC/ESR1)Gev} homozygotes

• tamoxifen treated mice exhibit colonic epithelium proliferation that is greater than in Gt(ROSA)26Sor^{tm1.1(MYC/ESR1)Gev} homozygotes

Genotype
MGI:3835358

cx18

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Tg(NES-TVA)J12Ech/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * FVB/N

mortality/aging

premature death ( J:125535 )

• after 84 days, mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB exhibit 40% compared to 50% survival in similarly treated Tg(NES-TVA)12Hev mice

neoplasm

increased glioma incidence ( J:125535 )

• 22 gliomas are discovered in 35 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 10 grade II (similar to human oligodendroglioma) and 12 grade III (similar to anaplastic oligodendroglioma)

nervous system

increased glioma incidence ( J:125535 )

• 22 gliomas are discovered in 35 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 10 grade II (similar to human oligodendroglioma) and 12 grade III (similar to anaplastic oligodendroglioma)

Genotype
MGI:5882410

cx19

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Tg(CKMM-tTA)A3Rhvh/0; Tg(tetO-Hgf,-EGFP)24Tcre/0
• Genetic Background: involves: 129X1/SvJ * FVB

muscle

skeletal muscle hyperplasia ( J:237183 )

• 32% of mice that develop embryonal rhabdomyosarcoma exhibit muscle hyperplasia while 68% of mice develop embryonal rhabdomyosarcoma without muscle hyperplasia

increased rhabdomyosarcoma incidence ( J:237183 )

• all mice develop tumors, mainly multi-step embryonal rhabdomyosarcoma with a short latency of 3.95 months

• embryonal rhabdomyosarcoma originates from satellite cells

• treatment of mice with doxycycline when tumors become palpable does not impair tumor growth

• mice maintained under doxycycline treatment until P10 develop tumors after doxycycline removal

neoplasm

increased rhabdomyosarcoma incidence ( J:237183 )

• all mice develop tumors, mainly multi-step embryonal rhabdomyosarcoma with a short latency of 3.95 months

• embryonal rhabdomyosarcoma originates from satellite cells

• treatment of mice with doxycycline when tumors become palpable does not impair tumor growth

• mice maintained under doxycycline treatment until P10 develop tumors after doxycycline removal

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
embryonal rhabdomyosarcoma		DOID:3246	OMIM:268210	J:237183

Genotype
MGI:5882411

cx20

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a⁺; Tg(CKMM-tTA)A3Rhvh/0; Tg(tetO-Hgf,-EGFP)24Tcre/0
• Genetic Background: involves: 129X1/SvJ * FVB

muscle

increased rhabdomyosarcoma incidence ( J:237183 )

• mice develop multi-step embryonal rhabdomyosarcoma with a latency of 6 months

• majority of tumors lose the wild-type allele

neoplasm

increased rhabdomyosarcoma incidence ( J:237183 )

• mice develop multi-step embryonal rhabdomyosarcoma with a latency of 6 months

• majority of tumors lose the wild-type allele

Genotype
MGI:3613023

cx21

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Sclt1^{Tg(CAG-sb10)1Dla}/0; TgTn(sb-T2/Onc)76Dla/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:99991 )

• mice died earlier than those homozygous for Cdkn2a^tm1Cjs alone

neoplasm

increased tumor incidence ( J:99991 )

• tumor spectrum was similar to Cdkn2a^tm1Cjs homozygotes and included malignant meningiomas

increased leukemia incidence ( J:99991 )

• myeloid leukemias were seen

increased lymphoma incidence ( J:99991 )

increased lung adenocarcinoma incidence ( J:99991 )

• a pulmonary adenocarcinoma was seen

increased sarcoma incidence ( J:99991 )

• soft tissue sarcomas or osteosarcomas

increased osteosarcoma incidence ( J:99991 )

respiratory system

increased lung adenocarcinoma incidence ( J:99991 )

• a pulmonary adenocarcinoma was seen

skeleton

increased osteosarcoma incidence ( J:99991 )

Genotype
MGI:3613024

cx22

• Allelic Composition: Cdkn2a^tm1Cjs/Cdkn2a^tm1Cjs; Sclt1^{Tg(CAG-sb10)1Dla}/0; TgTn(sb-T2/Onc)68Dla/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:99991 )

• mice died earlier than those homozygous for Cdkn2a^tm1Cjs alone

neoplasm

increased tumor incidence ( J:99991 )

• tumor spectrum was similar to Cdkn2a^tm1Cjs homozygotes and included malignant meningiomas

increased leukemia incidence ( J:99991 )

• myeloid leukemias were seen

increased lymphoma incidence ( J:99991 )

increased lung adenocarcinoma incidence ( J:99991 )

• a pulmonary adenocarcinoma was seen

increased sarcoma incidence ( J:99991 )

• soft tissue sarcomas or osteosarcomas

increased osteosarcoma incidence ( J:99991 )

respiratory system

increased lung adenocarcinoma incidence ( J:99991 )

• a pulmonary adenocarcinoma was seen

skeleton

increased osteosarcoma incidence ( J:99991 )